Clinical Biostatistics & Data Analysis

Interim Analyses in Rare Disease, Oncology and High-Risk Studies

November 18, 2025November 15, 2025 digi

Interim Analyses in Rare Disease, Oncology and High-Risk Studies Interim Analyses in Rare Disease, Oncology and High-Risk Studies Interim analyses play a crucial role in the management and success of clinical trials, especially in fields such as rare diseases, oncology, and high-risk studies. This tutorial provides a comprehensive step-by-step guide for clinical operations, regulatory affairs,…

Interim Analyses & Alpha Spending

Simulating Interim Strategies to Optimize Power and Type I Error

November 18, 2025November 15, 2025 digi

Simulating Interim Strategies to Optimize Power and Type I Error Simulating Interim Strategies to Optimize Power and Type I Error In the highly regulated environments of clinical trials, ensuring that methodologies for statistical analysis are both rigorous and compliant with FDA, EMA, and ICH-GCP guidelines is paramount. This article provides a comprehensive step-by-step tutorial guide…

Interim Analyses & Alpha Spending

Operationalizing Interim Analyses Across Global Trial Infrastructures

November 18, 2025November 15, 2025 digi

Operationalizing Interim Analyses Across Global Trial Infrastructures Operationalizing Interim Analyses Across Global Trial Infrastructures In the landscape of clinical research, interim analyses are pivotal in maintaining the integrity and efficiency of clinical trials. This step-by-step tutorial guide aims to illuminate the operationalization of interim analyses across various global trial infrastructures. Designed for clinical operations, regulatory…

Interim Analyses & Alpha Spending

Communicating Interim Results to Sponsors, Regulators and Investigators

November 18, 2025November 15, 2025 digi

Communicating Interim Results to Sponsors, Regulators and Investigators In the context of clinical trials, the communication of interim results is a critical aspect that can significantly influence decision-making processes for sponsors, regulators, and investigators. Interim analyses allow stakeholders to assess the progress and efficacy of the trial, which can lead to essential adjustments based on…

Interim Analyses & Alpha Spending

Estimands in Clinical Trials: From Concept to Implementation

November 18, 2025November 15, 2025 digi

Estimands in Clinical Trials: From Concept to Implementation Estimands in Clinical Trials: From Concept to Implementation The evolving landscape of clinical trials has introduced the concept of estimands, offering a structured framework for defining treatment effects while accounting for practical variables inherent in real-world situations. This tutorial provides an in-depth exploration of estimands, their significance,…

Estimands & Handling Intercurrent Events

Mapping Clinical Questions to Estimands Under ICH E9(R1)

November 18, 2025November 15, 2025 digi

Mapping Clinical Questions to Estimands Under ICH E9(R1) Mapping Clinical Questions to Estimands Under ICH E9(R1) The importance of accurately defining and interpreting estimands in clinical trial design is increasingly recognized in regulatory guidelines, particularly after the introduction of the ICH E9(R1) document, which focuses on the need to understand the clinical question being addressed….

Estimands & Handling Intercurrent Events

Identifying and Classifying Intercurrent Events That Impact Endpoints

November 18, 2025November 15, 2025 digi

Identifying and Classifying Intercurrent Events That Impact Endpoints Identifying and Classifying Intercurrent Events That Impact Endpoints In the realm of clinical trials, understanding intercurrent events and their potential impact on study endpoints is crucial. This article aims to provide clinical operations, regulatory affairs, and medical affairs professionals with a thorough, step-by-step guide to identifying and…

Estimands & Handling Intercurrent Events

Treatment Policy, Hypothetical and Composite Estimands: When to Use Each

November 18, 2025November 15, 2025 digi

Treatment Policy, Hypothetical and Composite Estimands: When to Use Each Treatment Policy, Hypothetical and Composite Estimands: When to Use Each In the realm of clinical research, particularly in the context of regulatory compliance and biostatistics, the concept of estimands has gained significant attention. Estimands provide a structured way to describe the treatment effect in clinical…

Estimands & Handling Intercurrent Events

Aligning Estimands Across Protocol, SAP and Clinical Study Report

November 18, 2025November 15, 2025 digi

Aligning Estimands Across Protocol, SAP and Clinical Study Report Aligning Estimands Across Protocol, SAP and Clinical Study Report In the evolving landscape of clinical trials, the integration of real world evidence in clinical trials has become crucial for various therapeutic areas, including conditions such as Crohn’s disease and ulcerative colitis. As regulatory bodies in the…

Estimands & Handling Intercurrent Events

Statistical Methods for Handling Intercurrent Events in Time-to-Event Data

November 18, 2025November 15, 2025 digi

Statistical Methods for Handling Intercurrent Events in Time-to-Event Data Statistical Methods for Handling Intercurrent Events in Time-to-Event Data In the complex landscape of clinical trials, particularly in the realms of Crohn’s disease clinical trials and ulcerative colitis clinical trials, it becomes imperative for researchers and professionals to comprehend how to effectively manage intercurrent events. An…

Estimands & Handling Intercurrent Events